ENDP
Endo International plc
Healthcare
01/27/2015
Presented
| Date | 01/23/2015 |
| Price | $78.87 |
| Market Cap | $12.10B |
| Ent Value | $15.83B |
| P/E Ratio | N/A |
| Book Value | $16.21 |
| Div Yield | N/A |
| Shares O/S | 153.88M |
| Ave Daily Vol | 1,900,000 |
| Short Int | 12.79% |
Current
| Price | $0.00 |
| Market Cap | $0.00B |
| Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. It provides branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel to treat and manage pain and conditions in urology, endocrinology, and oncology. The company also offers non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets; and pharmaceutical products in the areas of ADHD, pain, urology, and allergy. In addition, it provides various medical devices comprising AMS 700 MS series, AMS 800 artificial urinary sphincters, GreenLight XPS laser systems, Elevate anterior and posterior pelvic floor repair systems, and Monarc subfascial hammock products in the areas of men’s and women’s health, and prostate health. The company’s products also include Aveed, an injectable testosterone preparation to treat male hypogonadism; and BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. |
Publicly traded companies mentioned herein: Actavis plc (ACT), Auxilium Pharmaceuticals Inc. (AUXL), Endo International PLC (ENDP), Valeant Pharmaceuticals International Inc (VRX)
Highlights
The presenter is long shares of Endo International (ENDP), and believes the specialty pharmaceuticals company’s earnings power is substantial and misunderstood by the Street. He also is bullish on the acquisition of Auxilium, and noted that there is the potential for capital deployment to drive “significant” upside for shareholders. He sees the business model that ENDP is building as similar to Actavis’, and while there are some P&L risks the company is well diversified. “Overall, there is better visibility - with both ENDP and Actavis - than there is with Valeant,” he added.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.